BJSM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 24 October 2006. doi:10.1136/bjsm.2006.030643
British Journal of Sports Medicine 2007;41:e10
Copyright © 2007 BMJ Publishing Group Ltd & British Association of Sport and Exercise Medicine

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bjsm.2006.030643v1
41/8/e10    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagnaninchi, P.-O.
Right arrow Articles by Bosch, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagnaninchi, P.-O.
Right arrow Articles by Bosch, U

REVIEW

Tissue engineering for tendon repair

Pierre-Olivier Bagnaninchi1, Ying Yang1, Alicia J El Haj1, Nicola Maffulli2

1 Institute of Science and Technology in Medicine, Keele University, Hartshill, UK
2 Keele University School of Medicine, Hartshill, UK

Correspondence to:
Correspondence to:
N Maffulli
Keele University School of Medicine, Hartshill, UK;osa14{at}keele.ac.uk


ABSTRACT
Tissue engineering aims to induce tissue self-regeneration in vivo or to produce a functional tissue replacement in vitro to be then implanted in the body. To produce a viable and functional tendon, a uniaxially orientated collagen type I matrix has to be generated. Biochemical and physical factors can potentially alter both the production and the organisation of this matrix, and their combination in a dose- and time-dependent manner is probably the key to in vitro engineered tendons. This review discusses the role of these different factors affecting tenocyte growth in a three-dimensional environment in vivo and in vitro, and underlines the future challenge of tendon tissue engineering.


Abbreviations: bFGF, basic fibroblast growth factor; BMP, bone morphogenetic protein; ECM, extracellular matrix; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor


 

COMMENTARY

U Bosch3

3 International Neuroscience Institute, Orthopaedic Surgery, Sports Traumatology, Hannover, Germany; office{at}bosch-ini-hannover.de




This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
N. Maffulli and U. G. Longo
Conservative management for tendinopathy: is there enough scientific evidence?
Rheumatology, April 1, 2008; 47(4): 390 - 391.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Association of Sport and Exercise Medicine